<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014399</url>
  </required_header>
  <id_info>
    <org_study_id>PRC-ONCOLOGY-21-0628-PPG</org_study_id>
    <nct_id>NCT05014399</nct_id>
  </id_info>
  <brief_title>Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy</brief_title>
  <acronym>Chemo Brain</acronym>
  <official_title>Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph McCollom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Parkview Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see how the brain changes in patients receiving&#xD;
      chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer&#xD;
      Institute. This information will be used to identify helpful tests to diagnose individuals at&#xD;
      risk for developing difficulties with thinking and memory due to their cancer treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2021</start_date>
  <completion_date type="Anticipated">October 2030</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survey</measure>
    <time_frame>7 Years</time_frame>
    <description>FACT-Cog V3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Proteome Profiler Human XL Cytokine Array Kit (https://www.rndsystems.com/products/proteome-profiler-human-xl-cytokine-array-kit_ary022b)</measure>
    <time_frame>7 years</time_frame>
    <description>This panel of plasma factors will be will be used to detect protein from the blood of patients throughout and after chemotherapy treatment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neoplasm, Colorectal</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Cognitive Change</condition>
  <condition>Chemo-brain</condition>
  <condition>Chemo Fog</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Cognitive Decline</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory colorectal oncology patients undergoing cytotoxic therapy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent must be obtained and documented according to&#xD;
             International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the&#xD;
             local regulatory requirements, and permission to use private health information in&#xD;
             accordance with the Health Insurance Portability and Accountability Act (HIPAA) prior&#xD;
             to study-specific screening procedures. Must be able to provide study-specific&#xD;
             informed consent prior to study entry.&#xD;
&#xD;
          -  A histologically-confirmed colorectal tumor&#xD;
&#xD;
          -  Patients who will be treated with cytotoxic chemotherapies including Capecitabine,&#xD;
             Oxaliplatin, 5 fluorouracil, and Irinotecan are eligible.&#xD;
&#xD;
          -  Patients must not have received cytotoxic chemotherapy previous to enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior administration of anti-cancer chemotherapy, radiotherapy, immunotherapy, or&#xD;
             investigational agents&#xD;
&#xD;
          -  Patients having mental incompetence as assessed by study PI, which would hinder&#xD;
             completion of the surveys&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Any known brain metastases&#xD;
&#xD;
          -  Non-English speaking patients&#xD;
&#xD;
          -  Patients who have been diagnosed with any neuro-cognitive disorder including traumatic&#xD;
             brain injuries, Alzheimer's disease, Parkinson's disease, Huntington's disease, and&#xD;
             Creutzfeldt-Jakob disease.&#xD;
&#xD;
          -  Patients deemed inappropriate to participate in this study by the study PI or&#xD;
             coordinator will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>All self representation of gender identity accepted</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph McCollom, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parkview Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph McCollom, DO</last_name>
    <phone>260-266-7100</phone>
    <email>joseph.mccollom@parkview.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Powell, PHD</last_name>
    <email>emily.powell@parkview.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parkview Cancer Institute</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Joseph McCollom, DO</last_name>
      <phone>260-266-7100</phone>
      <email>joseph.mccollom@parkview.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Parkview Health</investigator_affiliation>
    <investigator_full_name>Joseph McCollom</investigator_full_name>
    <investigator_title>Oncologist</investigator_title>
  </responsible_party>
  <keyword>Palliative Care</keyword>
  <keyword>Palliative Oncology</keyword>
  <keyword>Supportive Care</keyword>
  <keyword>Supportive Oncology</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Chemo Brain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

